August 26, 2021 QUARTERLY REPORT – 2021 Q2
Posted at 08:23h
in quarterly-reports
QUARTERLY REPORT – 2021 Q2 View report (PDF)...
August 23, 2021 Vaccibody Q2 and half-year report 2021 webcast
Posted at 14:55h
in Uncategorized
Vaccibody Q2 and half-year report 2021 webcast View press release (PDF)...
July 12, 2021 Vaccibody enters into worldwide license agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in a second-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of concern
Posted at 09:40h
in Uncategorized
Vaccibody enters into worldwide license agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes View press release (PDF)...
June 29, 2021 Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern
Posted at 08:34h
in Uncategorized
Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates View press release (PDF)...
June 10, 2021 Vaccibody to present at Goldman Sachs 42nd Annual Global Healthcare Conference
Posted at 08:00h
in Uncategorized
Vaccibody to present at Goldman Sachs 42nd Annual Global Healthcare Conference View press release (PDF)...
June 1, 2021 Vaccibody to present at Jefferies Virtual Healthcare Conference (June 1-4, 2021)
Posted at 09:14h
in Uncategorized
Vaccibody to present at Jefferies Virtual Healthcare Conference (June 1-4, 2021) View announcement (PDF)...
May 12, 2021 Vaccibody appoints Mikkel Wandahl Pedersen as new Chief Scientific Officer and Agnete B. Fredriksen as Chief Innovation & Strategy Officer
Posted at 08:47h
in Uncategorized
Vaccibody appoints Mikkel Wandahl Pedersen as new Chief Scientific Officer and Agnete B. Fredriksen as Chief Innovation & Strategy Officer...
May 5, 2021 Vaccibody AS appoints Dr. Volck, M.D., Ph.D. as new member of the Board
Posted at 16:18h
in Uncategorized
View press release (PDF)...
May 5, 2021 MINUTES OF ANNUAL GENERAL MEETING IN VACCIBODY AS
Posted at 14:39h
in Uncategorized
View press release (PDF) MINUTES OF ANNUAL GENERAL MEETING IN VACCIBODY AS (PDF)...
April 30, 2021 Status update on VB C-02 clinical trial with VB10.16 and immune checkpoint inhibitor atezolizumab
Posted at 08:26h
in Uncategorized
Status update on VB C-02 clinical trial...